Sema Mandal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Sema Mandal has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Mary Ramsay
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK
6 shared publications - Hamish Mohammed
UK Health Security Agency
4 shared publications - Gayatri Amirthalingam
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
3 shared publications - Ruth Simmons
UK Health Security Agency London UK
3 shared publications Andre Charlett
Statistics, Modelling and Economics, Data, Analytics & Surveillance, UK Health Security Agency
2 shared publicationsBennet Dugbazah
Health Protection Operations, UK Health Security Agency
2 shared publications
Latest Publications
- Open Access
- 9 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (9) , e70205
Characterising Hepatitis D Virus in the UK From 2011 to 2021
Little is known about hepatitis B virus (HBV) and Hepatitis D virus (HDV) coinfection in the UK. HDV screening is recommended among all individuals with HBV, with coinfection associated with increased disease progression. Using data on HDV testing, shared by 11 laboratories in the UK who reported undertaking HDV testing, and national testing data for HBV we established a cohort of individuals tested for HDV, investigating testing pathways, describing characteristics and outcomes of those HDV‐RNA positive to inform targeted interventions for testing, diagnosis and linkage to care. Demographic information, clinical assessments, treatment and recent laboratory results from NHS trusts, and through linkage to national healthcare datasets was collected for HDV‐RNA positive individuals. Between 2011 and 2021, 42% of individuals newly diagnosed with HBV in England were linked to an HDV test. Anti‐HDV positivity was 5.0%, 55.8% were HDV‐RNA tested and 45.7% were ever HDV‐RNA positive. HDV‐RNA positivity in the absence of an anti‐HDV result was 6.4%. Among individuals who were HDV‐RNA positive, 94.3% were non‐UK born, with 24 different primary languages reported, 49% had evidence of treatment, and 48% had evidence of cirrhosis. 10% had died of which 58.4% died of liver disease. In conclusion, our findings indicate that HDV testing in HBV positive individuals in the UK is sub‐optimal against testing guidelines, including RNA testing among those who are anti‐HDV positive. Considerable work is needed to improve the patient care pathway, to ensure patients are appropriately diagnosed, linked and retained in care, with adequate access to treatment.
- 9 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (9) , e70205
Open AccessCharacterising Hepatitis D Virus in the UK From 2011 to 2021
Little is known about hepatitis B virus (HBV) and Hepatitis D virus (HDV) coinfection in the UK. HDV screening is recommended among all individuals with HBV, with coinfection associated with increased disease progression. Using data on HDV testing, shared by 11 laboratories in the UK who reported undertaking HDV testing, and national testing data for HBV we established a cohort of individuals tested for HDV, investigating testing pathways, describing characteristics and outcomes of those HDV‐RNA positive to inform targeted interventions for testing, diagnosis and linkage to care. Demographic information, clinical assessments, treatment and recent laboratory results from NHS trusts, and through linkage to national healthcare datasets was collected for HDV‐RNA positive individuals. Between 2011 and 2021, 42% of individuals newly diagnosed with HBV in England were linked to an HDV test. Anti‐HDV positivity was 5.0%, 55.8% were HDV‐RNA tested and 45.7% were ever HDV‐RNA positive. HDV‐RNA positivity in the absence of an anti‐HDV result was 6.4%. Among individuals who were HDV‐RNA positive, 94.3% were non‐UK born, with 24 different primary languages reported, 49% had evidence of treatment, and 48% had evidence of cirrhosis. 10% had died of which 58.4% died of liver disease. In conclusion, our findings indicate that HDV testing in HBV positive individuals in the UK is sub‐optimal against testing guidelines, including RNA testing among those who are anti‐HDV positive. Considerable work is needed to improve the patient care pathway, to ensure patients are appropriately diagnosed, linked and retained in care, with adequate access to treatment.
- Open Access
- 1 January 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 30 (7) , 1-14
The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
Background: People who inject drugs are disproportionately affected by hepatitis C virus. The emergence of direct-acting antiviral treatments for hepatitis C virus motivated England to achieve the World Health Organization’s elimination target of decreasing hepatitis C virus incidence among people who inject drugs to < 2 per 100 person-years (/100 person-years) by 2030. We determined whether existing testing and treatment strategies will reach this target in England, or whether improved strategies are needed and whether they are cost-effective. Methods: A dynamic hepatitis C virus transmission model among people who inject drugs was developed for four English regions. The model included the pathway from testing to treatment in prisons, drug treatment centres and other settings. Each pathway was parameterised using region-specific data, with yearly bio-behavioural surveys among people who inject drugs being used to parameterise and calibrate the model in a Bayesian framework. The model projected whether each region will reach the hepatitis C virus incidence target or what improvements (in testing and linkage to treatment) are needed from 2024 to achieve it. Hepatitis C virus care pathway costs were collated through interviews with practitioners and the published literature. The mean incremental cost-effectiveness ratio (per quality-adjusted life-year saved) was estimated for any ‘improved’ strategy that reached the incidence target compared to the baseline strategy. Incremental cost-effectiveness ratios were compared to a willingness-to-pay threshold of £20,000/quality-adjusted life-year saved over a 50-year time horizon (3.5% annual discount rate). Results: Across the four regions over 2016–22, an estimated 8831–9689 treatments occurred among 37,230 people who inject drugs, with the annual number treated increasing in prisons (7.8 times) and drug treatment centres (3.6 times). Model projections suggest that hepatitis C virus incidence among people who inject drugs has decreased across the regions by 56.1–85.4% (range of medians) over 2015–22, with incidence decreasing by 79.7–98.6% to 0.2–2.2/100 person-years by 2030. The World Health Organization incidence target (< 2/100 person-years) will be reached with > 80% probability in three regions and 40% probability in the other region. The probability of reaching the incidence target increases to > 65% in this region if screening is increased in drug treatment centres (80% screened annually) or prisons (75% of people get tested during their prison stay), with these screening strategies being cost-effective. Conclusion: Numerous England regions may be on target to decrease hepatitis C virus incidence among people who inject drugs to < 2/100 person-years. In regions that are not on target, further scale-up of testing in drug treatment centre or prison from 2024 could enable them to reach the World Health Organization elimination target and be cost-effective. Limitations: Projections were based on model estimations, which need to be confirmed with empirical data. Data uncertainties affected our model projections, including uncertainty in the number of people who inject drugs in each region and the number of treatments given to people who inject drugs in different settings. Sample sizes for the yearly bio-behavioural surveys among people who inject drugs were small, and so samples were pooled over multiple years. Testing rates among people who inject drugs could not be directly estimated because the sentinel surveillance had incomplete coverage and could not identify people who inject drugs; testing rates were estimated through model calibration. Future work: There is interest in understanding what scale-back in testing can occur after 2030 without resulting in a rebound in hepatitis C virus incidence, and in developing models for each devolved nation to determine their progress to World Health Organization hepatitis C virus elimination targets. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128513.
- 1 January 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 30 (7) , 1-14
Open AccessThe impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
Background: People who inject drugs are disproportionately affected by hepatitis C virus. The emergence of direct-acting antiviral treatments for hepatitis C virus motivated England to achieve the World Health Organization’s elimination target of decreasing hepatitis C virus incidence among people who inject drugs to < 2 per 100 person-years (/100 person-years) by 2030. We determined whether existing testing and treatment strategies will reach this target in England, or whether improved strategies are needed and whether they are cost-effective. Methods: A dynamic hepatitis C virus transmission model among people who inject drugs was developed for four English regions. The model included the pathway from testing to treatment in prisons, drug treatment centres and other settings. Each pathway was parameterised using region-specific data, with yearly bio-behavioural surveys among people who inject drugs being used to parameterise and calibrate the model in a Bayesian framework. The model projected whether each region will reach the hepatitis C virus incidence target or what improvements (in testing and linkage to treatment) are needed from 2024 to achieve it. Hepatitis C virus care pathway costs were collated through interviews with practitioners and the published literature. The mean incremental cost-effectiveness ratio (per quality-adjusted life-year saved) was estimated for any ‘improved’ strategy that reached the incidence target compared to the baseline strategy. Incremental cost-effectiveness ratios were compared to a willingness-to-pay threshold of £20,000/quality-adjusted life-year saved over a 50-year time horizon (3.5% annual discount rate). Results: Across the four regions over 2016–22, an estimated 8831–9689 treatments occurred among 37,230 people who inject drugs, with the annual number treated increasing in prisons (7.8 times) and drug treatment centres (3.6 times). Model projections suggest that hepatitis C virus incidence among people who inject drugs has decreased across the regions by 56.1–85.4% (range of medians) over 2015–22, with incidence decreasing by 79.7–98.6% to 0.2–2.2/100 person-years by 2030. The World Health Organization incidence target (< 2/100 person-years) will be reached with > 80% probability in three regions and 40% probability in the other region. The probability of reaching the incidence target increases to > 65% in this region if screening is increased in drug treatment centres (80% screened annually) or prisons (75% of people get tested during their prison stay), with these screening strategies being cost-effective. Conclusion: Numerous England regions may be on target to decrease hepatitis C virus incidence among people who inject drugs to < 2/100 person-years. In regions that are not on target, further scale-up of testing in drug treatment centre or prison from 2024 could enable them to reach the World Health Organization elimination target and be cost-effective. Limitations: Projections were based on model estimations, which need to be confirmed with empirical data. Data uncertainties affected our model projections, including uncertainty in the number of people who inject drugs in each region and the number of treatments given to people who inject drugs in different settings. Sample sizes for the yearly bio-behavioural surveys among people who inject drugs were small, and so samples were pooled over multiple years. Testing rates among people who inject drugs could not be directly estimated because the sentinel surveillance had incomplete coverage and could not identify people who inject drugs; testing rates were estimated through model calibration. Future work: There is interest in understanding what scale-back in testing can occur after 2030 without resulting in a rebound in hepatitis C virus incidence, and in developing models for each devolved nation to determine their progress to World Health Organization hepatitis C virus elimination targets. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128513.
- Open Access
- 28 July 2025
- Published by Elsevier in The Lancet Public Health
- Vol. 10 (8) , e641-e642
Hepatitis A targeted vaccination in England: a system challenge
- 28 July 2025
- Published by Elsevier in The Lancet Public Health
- Vol. 10 (8) , e641-e642
Open AccessHepatitis A targeted vaccination in England: a system challenge
- Open Access
- 31 May 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-7
Developing a syndromic surveillance tool to support the epidemiological investigation into paediatric acute hepatitis of unknown aetiology in England
Background: During 2022, a new public health threat emerged when cases of paediatric acute hepatitis of unknown aetiology (HUA) were identified in children aged under 16 years old in the United Kingdom (UK). At the time, the epidemiology and extent of cases was based upon limited and non-standardised reporting from hospitals and liver units. We aimed to adapt existing real-time syndromic surveillance systems to support the epidemiological investigation of cases of HUA presenting to emergency departments (EDs) in England. Methods: Syndromic surveillance is generally based on the collection of patient symptoms or chief complaints, which are collected using automated routines in near real-time. Here, we used an existing ED syndromic surveillance system monitoring daily patient attendances across a network of approximately 150 EDs in England. Clinical diagnosis codes related to the potential symptoms associated with the HUA incident were selected and attendance data monitored retrospectively and prospectively during the incident. Results: From 2 April 2018 to 31 December 2021, there were small sporadic numbers of daily ED attendances for ‘liver conditions’ in children with no observed secular trends or seasonality across the 1 to 4 and 5 to 14 years age groups. The period 2 April to 29 July was compared across each year included in the analysis. Mean daily HUA attendances during 2018 to 2021 was 0.05 and 0.22 for 1 to 4 and 5 to 14 years respectively, however in 2022 there were 0.26 and 0.42 mean daily attendances. This represented an increase of 377% and 94% in the 1 to 4 and 5 to 14 years age groups, respectively. From June 2022, daily syndromic ‘liver condition’ attendances appeared to decrease and the rate of increase in cumulative attendances slowed. Conclusions: We demonstrate how syndromic surveillance provided support to the HUA outbreak using an existing syndromic surveillance framework to develop new indicators based on the newly emerging clinical symptoms. The outputs from the syndromic tool matched clinical and epidemiological findings with respect to trends in other HUA-related data, including clinical and laboratory reports, over time. This work demonstrates the potential for syndromic surveillance supporting the epidemiological surveillance of hepatitis and providing a valuable tool for the real-time management of future unknown health threats.
- 31 May 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-7
Open AccessDeveloping a syndromic surveillance tool to support the epidemiological investigation into paediatric acute hepatitis of unknown aetiology in England
Background: During 2022, a new public health threat emerged when cases of paediatric acute hepatitis of unknown aetiology (HUA) were identified in children aged under 16 years old in the United Kingdom (UK). At the time, the epidemiology and extent of cases was based upon limited and non-standardised reporting from hospitals and liver units. We aimed to adapt existing real-time syndromic surveillance systems to support the epidemiological investigation of cases of HUA presenting to emergency departments (EDs) in England. Methods: Syndromic surveillance is generally based on the collection of patient symptoms or chief complaints, which are collected using automated routines in near real-time. Here, we used an existing ED syndromic surveillance system monitoring daily patient attendances across a network of approximately 150 EDs in England. Clinical diagnosis codes related to the potential symptoms associated with the HUA incident were selected and attendance data monitored retrospectively and prospectively during the incident. Results: From 2 April 2018 to 31 December 2021, there were small sporadic numbers of daily ED attendances for ‘liver conditions’ in children with no observed secular trends or seasonality across the 1 to 4 and 5 to 14 years age groups. The period 2 April to 29 July was compared across each year included in the analysis. Mean daily HUA attendances during 2018 to 2021 was 0.05 and 0.22 for 1 to 4 and 5 to 14 years respectively, however in 2022 there were 0.26 and 0.42 mean daily attendances. This represented an increase of 377% and 94% in the 1 to 4 and 5 to 14 years age groups, respectively. From June 2022, daily syndromic ‘liver condition’ attendances appeared to decrease and the rate of increase in cumulative attendances slowed. Conclusions: We demonstrate how syndromic surveillance provided support to the HUA outbreak using an existing syndromic surveillance framework to develop new indicators based on the newly emerging clinical symptoms. The outputs from the syndromic tool matched clinical and epidemiological findings with respect to trends in other HUA-related data, including clinical and laboratory reports, over time. This work demonstrates the potential for syndromic surveillance supporting the epidemiological surveillance of hepatitis and providing a valuable tool for the real-time management of future unknown health threats.
- Open Access
Mpox vaccination uptake in a UK community sample of gay, bisexual, and other men who have sex with men (GBMSM) the year following the 2022 Clade IIb mpox outbreak
Mpox is an infectious disease transmitted through close contact. It is caused by the monkeypox virus, which is endemic to some countries of West and Central Africa. A multi-country outbreak of mpox occurred in 2022, and the UK experienced rapid community transmission associated with sexual contact, mainly, but not exclusively among networks of gay, bisexual, and other men who have sex with men (GBMSM). In response to the outbreak in the UK, a reactive mpox vaccination programme was targeted to those most at risk. We explore the uptake and course completion of mpox vaccination in GBMSM taking part in an online survey in 2023. Findings from this community sample indicate vaccination uptake in around two-thirds of participants meeting mpox proxy eligibility criteria with high levels of course completion among all and eligible participants that were ever vaccinated. Vaccine non-offer was a barrier to uptake, as nearly a third of those eligible but unvaccinated reported never having received an mpox vaccine offer. Continued targeting of vaccination to GBMSM at highest risk of mpox at SHS, with community-support, will help facilitate equitable uptake of vaccination.
Open AccessMpox vaccination uptake in a UK community sample of gay, bisexual, and other men who have sex with men (GBMSM) the year following the 2022 Clade IIb mpox outbreak
Mpox is an infectious disease transmitted through close contact. It is caused by the monkeypox virus, which is endemic to some countries of West and Central Africa. A multi-country outbreak of mpox occurred in 2022, and the UK experienced rapid community transmission associated with sexual contact, mainly, but not exclusively among networks of gay, bisexual, and other men who have sex with men (GBMSM). In response to the outbreak in the UK, a reactive mpox vaccination programme was targeted to those most at risk. We explore the uptake and course completion of mpox vaccination in GBMSM taking part in an online survey in 2023. Findings from this community sample indicate vaccination uptake in around two-thirds of participants meeting mpox proxy eligibility criteria with high levels of course completion among all and eligible participants that were ever vaccinated. Vaccine non-offer was a barrier to uptake, as nearly a third of those eligible but unvaccinated reported never having received an mpox vaccine offer. Continued targeting of vaccination to GBMSM at highest risk of mpox at SHS, with community-support, will help facilitate equitable uptake of vaccination.
- Open Access
Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England
Background In 2022, a global outbreak of mpox occurred among gay and bisexual men who have sex with men (GBMSM). In England, the outbreak was controlled through reductions in sexual risk behaviour and vaccination of high-risk GBMSM. However, mpox continues to circulate and so future outbreaks could occur. We evaluated the most cost-effective vaccination strategy to minimise future mpox outbreaks among GBMSM in England. Methods A mathematical model of mpox transmission among GBMSM was developed to estimate the costs per quality-adjusted-life-year (QALY) gained for different vaccination strategies starting in 2024 (20-year time-horizon; 3.5% discount rate; willingness-to-pay threshold £20,000/QALY). The model was calibrated using English surveillance data from the 2022 outbreak and two community surveys. Reactive vaccination (only during outbreaks) and pre-emptive vaccination (continuous routine) strategies targeting high-risk GBMSM were compared to no vaccination. Baseline projections assumed vaccine effectiveness of 78%/89% for 5/10 years with 1/2 doses at £160/dose. Costs were estimated for case management, vaccination and public health responses (PHR) during an outbreak. Findings All vaccination strategies reduced costs and gained QALYs compared to no vaccination. Continuous pre-emptive vaccination (daily rate 41 doses) was most cost-effective, saving £39.56 million and gaining 547.6 QALYs over 20-years. Threshold analyses suggested vaccination of high-risk GBMSM is cost-effective if the vaccine costs <£701/dose. Pre-emptive vaccination remains the optimal strategy across numerous sensitivity analyses, but the optimal vaccination rate can vary. Reactive vaccination only becomes more cost-effective when PHR costs are not included. Interpretation Pre-emptive vaccination of high-risk GBMSM is a cost-saving strategy to prevent future mpox outbreaks. Funding NIHR Extended funding statement This study was funded by the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol NIHR200877, in partnership with UK Health Security Agency (UKHSA). The views expressed are those of the author and not necessarily those of the NIHR, the Department of Health and Social Care, or UKHSA. Evidence before this study The global outbreak of mpox in 2022 predominantly affected gay, bisexual, and other men who have sex with men (GBMSM). After a steep rise in cases over May to June 2022, the rate of cases of mpox decreased dramatically after July 2022, thought to be due to the roll-out of vaccination programmes in many countries and reductions in sexual risk behaviour among GBMSM. Despite this decline in cases, new infections of mpox have occurred among GBMSM in many countries in 2023, raising concerns that new outbreaks could occur especially if levels of vaccine-induced protection reduce over time. We searched PubMed, bioRxiv and medRxiv for articles published from beginning May 2022 to 28 June 2024 with the following keywords: ((“monkeypox” OR “mpox” OR “mpx”) AND (“model” OR “modelling” OR “modeling”) AND (“vaccine” OR “vaccination” OR “cost-effectiveness” OR “cost-effective”)). Although this search identified many articles involving transmission modelling that assessed the impact of various interventions on mpox transmission, only eight provided insights on what is needed to prevent future outbreaks, just one considered the cost implications of vaccinating for mpox, and none evaluated the cost-effectiveness of vaccination. Existing model analyses have evaluated what interventions are needed to control outbreaks showing that future outbreaks could be controlled by vaccinating close contacts of cases and individuals in large sexual networks, as well as pre-emptively vaccinating high-risk individuals prior to outbreaks occurring. None of these analyses used detailed data to calibrate their models to actual settings, reducing their real-world relevance. Conversely, other model analyses undertook detailed modelling for specific settings (Canada, Netherlands and England), and showed that existing levels of vaccine roll-out may have reduced the magnitude of future outbreaks. However, these analyses did not model possible future vaccination strategies. The only economic analysis for mpox compared the costs of vaccination to not vaccinating the general population in Jeddah, Saudi Arabia, suggesting that vaccination costs more than not vaccinating, although vaccinating the general population is an unrealistic strategy. Unfortunately, this economic analysis used implausible data (respiratory infection contact rates) to simulate the transmission of mpox, did not use recent data to estimate transmissibility, did not focus on GBMSM, and used very little data on the health-related costs of mpox disease. Added value of this study This economic analysis extends our understanding of what is needed to control future outbreaks of mpox among GBMSM in England and other settings. Combining a previously validated model of mpox infection in England with real data on the costs of care for mpox, vaccination and public health responses, we undertook an economic analysis to evaluate the most cost-effective future vaccination strategy to prevent future mpox outbreaks. We model either reactive (only vaccinate during outbreaks) or pre-emptive (routine vaccination irrespective of outbreaks) vaccination strategies targeting high-risk GBMSM. Our analyses show that all modelled vaccination strategies are likely to be cost-saving and improve quality of life compared to not vaccinating, with continuous pre-emptive vaccination at a low rate (daily rate 41 doses) being the most cost-effective strategy. This finding is robust over most sensitivity analyses with mpox vaccination remaining cost-effective if the vaccine price is less than £701 per dose. Implications of all the available evidence Ongoing importation of new sexually transmitted mpox cases in many non-endemic countries means that these countries need to be prepared for future mpox outbreaks if immunity levels fall or if the pool of unvaccinated people increases to a large extent. Our analyses give robust evidence that mpox vaccination is a cost-saving strategy for minimizing the likelihood of future mpox outbreaks in England and other comparable countries. These findings have been used as evidence by the UK Joint Committee on Vaccination and Immunisation to recommend a pre-emptive (routine) vaccination programme of high-risk GBMSM through sexual health services in the UK. Other countries should seriously consider similar strategies to prevent future outbreaks.
Open AccessCost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England
Background In 2022, a global outbreak of mpox occurred among gay and bisexual men who have sex with men (GBMSM). In England, the outbreak was controlled through reductions in sexual risk behaviour and vaccination of high-risk GBMSM. However, mpox continues to circulate and so future outbreaks could occur. We evaluated the most cost-effective vaccination strategy to minimise future mpox outbreaks among GBMSM in England. Methods A mathematical model of mpox transmission among GBMSM was developed to estimate the costs per quality-adjusted-life-year (QALY) gained for different vaccination strategies starting in 2024 (20-year time-horizon; 3.5% discount rate; willingness-to-pay threshold £20,000/QALY). The model was calibrated using English surveillance data from the 2022 outbreak and two community surveys. Reactive vaccination (only during outbreaks) and pre-emptive vaccination (continuous routine) strategies targeting high-risk GBMSM were compared to no vaccination. Baseline projections assumed vaccine effectiveness of 78%/89% for 5/10 years with 1/2 doses at £160/dose. Costs were estimated for case management, vaccination and public health responses (PHR) during an outbreak. Findings All vaccination strategies reduced costs and gained QALYs compared to no vaccination. Continuous pre-emptive vaccination (daily rate 41 doses) was most cost-effective, saving £39.56 million and gaining 547.6 QALYs over 20-years. Threshold analyses suggested vaccination of high-risk GBMSM is cost-effective if the vaccine costs <£701/dose. Pre-emptive vaccination remains the optimal strategy across numerous sensitivity analyses, but the optimal vaccination rate can vary. Reactive vaccination only becomes more cost-effective when PHR costs are not included. Interpretation Pre-emptive vaccination of high-risk GBMSM is a cost-saving strategy to prevent future mpox outbreaks. Funding NIHR Extended funding statement This study was funded by the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol NIHR200877, in partnership with UK Health Security Agency (UKHSA). The views expressed are those of the author and not necessarily those of the NIHR, the Department of Health and Social Care, or UKHSA. Evidence before this study The global outbreak of mpox in 2022 predominantly affected gay, bisexual, and other men who have sex with men (GBMSM). After a steep rise in cases over May to June 2022, the rate of cases of mpox decreased dramatically after July 2022, thought to be due to the roll-out of vaccination programmes in many countries and reductions in sexual risk behaviour among GBMSM. Despite this decline in cases, new infections of mpox have occurred among GBMSM in many countries in 2023, raising concerns that new outbreaks could occur especially if levels of vaccine-induced protection reduce over time. We searched PubMed, bioRxiv and medRxiv for articles published from beginning May 2022 to 28 June 2024 with the following keywords: ((“monkeypox” OR “mpox” OR “mpx”) AND (“model” OR “modelling” OR “modeling”) AND (“vaccine” OR “vaccination” OR “cost-effectiveness” OR “cost-effective”)). Although this search identified many articles involving transmission modelling that assessed the impact of various interventions on mpox transmission, only eight provided insights on what is needed to prevent future outbreaks, just one considered the cost implications of vaccinating for mpox, and none evaluated the cost-effectiveness of vaccination. Existing model analyses have evaluated what interventions are needed to control outbreaks showing that future outbreaks could be controlled by vaccinating close contacts of cases and individuals in large sexual networks, as well as pre-emptively vaccinating high-risk individuals prior to outbreaks occurring. None of these analyses used detailed data to calibrate their models to actual settings, reducing their real-world relevance. Conversely, other model analyses undertook detailed modelling for specific settings (Canada, Netherlands and England), and showed that existing levels of vaccine roll-out may have reduced the magnitude of future outbreaks. However, these analyses did not model possible future vaccination strategies. The only economic analysis for mpox compared the costs of vaccination to not vaccinating the general population in Jeddah, Saudi Arabia, suggesting that vaccination costs more than not vaccinating, although vaccinating the general population is an unrealistic strategy. Unfortunately, this economic analysis used implausible data (respiratory infection contact rates) to simulate the transmission of mpox, did not use recent data to estimate transmissibility, did not focus on GBMSM, and used very little data on the health-related costs of mpox disease. Added value of this study This economic analysis extends our understanding of what is needed to control future outbreaks of mpox among GBMSM in England and other settings. Combining a previously validated model of mpox infection in England with real data on the costs of care for mpox, vaccination and public health responses, we undertook an economic analysis to evaluate the most cost-effective future vaccination strategy to prevent future mpox outbreaks. We model either reactive (only vaccinate during outbreaks) or pre-emptive (routine vaccination irrespective of outbreaks) vaccination strategies targeting high-risk GBMSM. Our analyses show that all modelled vaccination strategies are likely to be cost-saving and improve quality of life compared to not vaccinating, with continuous pre-emptive vaccination at a low rate (daily rate 41 doses) being the most cost-effective strategy. This finding is robust over most sensitivity analyses with mpox vaccination remaining cost-effective if the vaccine price is less than £701 per dose. Implications of all the available evidence Ongoing importation of new sexually transmitted mpox cases in many non-endemic countries means that these countries need to be prepared for future mpox outbreaks if immunity levels fall or if the pool of unvaccinated people increases to a large extent. Our analyses give robust evidence that mpox vaccination is a cost-saving strategy for minimizing the likelihood of future mpox outbreaks in England and other comparable countries. These findings have been used as evidence by the UK Joint Committee on Vaccination and Immunisation to recommend a pre-emptive (routine) vaccination programme of high-risk GBMSM through sexual health services in the UK. Other countries should seriously consider similar strategies to prevent future outbreaks.
- Open Access
Factors associated with human papillomavirus, hepatitis A, hepatitis B and mpox vaccination uptake among gay, bisexual and other men who have sex with men in the UK – findings from the large community-based RiiSH-Mpox survey
Background Gay, bisexual, and other men who have sex with men (GBMSM) face a disproportionate burden of sexually transmitted infections and are eligible for targeted vaccinations for hepatitis A (HAV), hepatitis B (HBV), human papilloma virus (HPV) and mpox. This study examines the sociodemographic characteristics, sexual behaviours, and sexual healthcare service (SHS) use associated with vaccination uptake. Methods We undertook analyses of RiiSH-Mpox - an online, community-based survey with GBMSM recruited via social media and dating apps. We calculated vaccination uptake (≥1 dose) among eligible GBMSM. Bivariate and multivariable logistic regression was performed to identify factors independently associated with vaccination uptake among eligible participants. Results Reported uptake in eligible GBMSM was around two-thirds for each of the vaccinations considered: mpox 69% (95% confidence interval (CI): 66%-72%), HAV 68% (CI:65%-70%), HBV 72% (CI:69%-74%) and HPV 65% (CI:61%-68%). Vaccination course completion (receiving all recommended doses) ranged from 75% (HBV) to 89% (HAV) among eligible GBMSM. Individuals who represented missed opportunities for vaccination ranged from 22-30% of eligible SHS attendees. Younger participants, individuals identifying as bisexual, reporting lower educational qualifications, or being unemployed reported lower uptake across GBMSM-selective vaccinations. Individuals who reported greater levels of sexual behaviour and recent SHS use were more likely to report vaccinations. Conclusion Eligible participants reported high uptake of vaccinations; however, uptake was lower amongst young GBMSM and self-identifying bisexual men. Awareness of groups with lower vaccination uptake will help inform practice, delivery strategies and health promotion, to improve the reach and impact of vaccinations amongst GBMSM. Contributions DP, RW, KF, CHM, JS, HM reviewed and updated the survey instrument. Survey implementation, data collection and data management were carried out by RW and DO. GB, CM, DO, HM curated secondary analysis plan with review and contributions from KF, MC, JS, RS, SM. GB conducted analysis and completed the first manuscript draft. All authors contributed to successive drafts and reviewed and approved the final manuscript. Ethics statement Ethical approval of this study was provided by the UKHSA Research and Ethics Governance Group (REGG; ref: R&D 524). Online informed consent was received from all participants and all methods were performed in accordance with guidelines and regulations set by the UKHSA REGG. Competing interests Authors have no competing interests to declare. Data availability statement The data that support the findings of this study are available upon reasonable request from the UK Health Security Agency (UKHSA). Requests can be directed to Dr Hamish Mohammed ( hamish.mohammed{at}ukhsa.gov.uk ). Funding This study did not receive any funding and was conducted as part of the UKHSA public health response to mpox.
Open AccessFactors associated with human papillomavirus, hepatitis A, hepatitis B and mpox vaccination uptake among gay, bisexual and other men who have sex with men in the UK – findings from the large community-based RiiSH-Mpox survey
Background Gay, bisexual, and other men who have sex with men (GBMSM) face a disproportionate burden of sexually transmitted infections and are eligible for targeted vaccinations for hepatitis A (HAV), hepatitis B (HBV), human papilloma virus (HPV) and mpox. This study examines the sociodemographic characteristics, sexual behaviours, and sexual healthcare service (SHS) use associated with vaccination uptake. Methods We undertook analyses of RiiSH-Mpox - an online, community-based survey with GBMSM recruited via social media and dating apps. We calculated vaccination uptake (≥1 dose) among eligible GBMSM. Bivariate and multivariable logistic regression was performed to identify factors independently associated with vaccination uptake among eligible participants. Results Reported uptake in eligible GBMSM was around two-thirds for each of the vaccinations considered: mpox 69% (95% confidence interval (CI): 66%-72%), HAV 68% (CI:65%-70%), HBV 72% (CI:69%-74%) and HPV 65% (CI:61%-68%). Vaccination course completion (receiving all recommended doses) ranged from 75% (HBV) to 89% (HAV) among eligible GBMSM. Individuals who represented missed opportunities for vaccination ranged from 22-30% of eligible SHS attendees. Younger participants, individuals identifying as bisexual, reporting lower educational qualifications, or being unemployed reported lower uptake across GBMSM-selective vaccinations. Individuals who reported greater levels of sexual behaviour and recent SHS use were more likely to report vaccinations. Conclusion Eligible participants reported high uptake of vaccinations; however, uptake was lower amongst young GBMSM and self-identifying bisexual men. Awareness of groups with lower vaccination uptake will help inform practice, delivery strategies and health promotion, to improve the reach and impact of vaccinations amongst GBMSM. Contributions DP, RW, KF, CHM, JS, HM reviewed and updated the survey instrument. Survey implementation, data collection and data management were carried out by RW and DO. GB, CM, DO, HM curated secondary analysis plan with review and contributions from KF, MC, JS, RS, SM. GB conducted analysis and completed the first manuscript draft. All authors contributed to successive drafts and reviewed and approved the final manuscript. Ethics statement Ethical approval of this study was provided by the UKHSA Research and Ethics Governance Group (REGG; ref: R&D 524). Online informed consent was received from all participants and all methods were performed in accordance with guidelines and regulations set by the UKHSA REGG. Competing interests Authors have no competing interests to declare. Data availability statement The data that support the findings of this study are available upon reasonable request from the UK Health Security Agency (UKHSA). Requests can be directed to Dr Hamish Mohammed ( hamish.mohammed{at}ukhsa.gov.uk ). Funding This study did not receive any funding and was conducted as part of the UKHSA public health response to mpox.
- Open Access
Post-peak mpox in England: epidemiology, reinfection, and vaccine effectiveness – data from 2023
England, like other countries that experienced a large outbreak of emergent mpox in 2022, continued to record cases during 2023 at a low but steady frequency. Comprehensive national surveillance shows that cases continue to occur primarily among gay, bisexual and other men who have sex with men mostly in London. Of 137 cases in 2023, around half were acquired overseas, half were vaccinated, and one case of reinfection was reported. Eleven people required hospital care. High vaccination uptake, during 2022, has provided good coverage of those at higher risk of mpox. Using the screening method, vaccine effectiveness of one dose was estimated at 84%. None of the vaccinated cases in 2023 were hospitalised.
Open AccessPost-peak mpox in England: epidemiology, reinfection, and vaccine effectiveness – data from 2023
England, like other countries that experienced a large outbreak of emergent mpox in 2022, continued to record cases during 2023 at a low but steady frequency. Comprehensive national surveillance shows that cases continue to occur primarily among gay, bisexual and other men who have sex with men mostly in London. Of 137 cases in 2023, around half were acquired overseas, half were vaccinated, and one case of reinfection was reported. Eleven people required hospital care. High vaccination uptake, during 2022, has provided good coverage of those at higher risk of mpox. Using the screening method, vaccine effectiveness of one dose was estimated at 84%. None of the vaccinated cases in 2023 were hospitalised.
- Open Access
- 26 September 2023
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 7 (11) , 786-796
Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK
- 26 September 2023
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 7 (11) , 786-796
Open AccessPaediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK
- Open Access
- 26 September 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-14
A scoping review of media campaign strategies used to reach populations living with or at high risk for Hepatitis C in high income countries to inform future national campaigns in the United Kingdom
With the advent of direct acting antivirals, the World Health Organisation proposed eliminating Hepatitis C as a public health threat by 2030. To achieve this, countries need to diagnose, engage in care and treat their undiagnosed populations. This will require sensitisation campaigns. However previous media campaigns have had mixed impact. We conducted a scoping review to identify and understand the impact of previous Hepatitis C media campaigns. These findings could inform the delivery of future campaigns. We searched five electronic databases for published literature on media campaigns conducted for Hepatitis C awareness, testing, and treatment in Organisation for Economic Co-operation and Development (OECD) countries since 2010. Two independent reviewers screened citations for inclusion. Additionally, we spoke to stakeholders in the Hepatitis C field in the UK and conducted a Google search to identify any unpublished literature. A quantitative synthesis was conducted to identify targeted populations, strategies and media used, aims and impact of the campaigns. A title and year of publication screening of 3815 citations resulted in 113 papers that had a full abstract screen. This left 50 full-text papers, 18 were included of which 9 (50%) were from Europe. 5 (27.8%) of campaigns targeted minority ethnicities, and 9 (50%) aimed to increase testing. A Google search identified 6 grey literature sources. Most campaigns were not evaluated for impact. Discussions with stakeholders identified several barriers to successful campaigns including lack of targeted messaging, stigmatising or accusatory messaging, and short-lived or intermittent campaign strategies. Future campaigns will likely need to be multifaceted and have multiple tailored interventions. Campaigns will need to be sizeable and robust, integrated into health systems and viewed as an ongoing service rather than one-offs.
- 26 September 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-14
Open AccessA scoping review of media campaign strategies used to reach populations living with or at high risk for Hepatitis C in high income countries to inform future national campaigns in the United Kingdom
With the advent of direct acting antivirals, the World Health Organisation proposed eliminating Hepatitis C as a public health threat by 2030. To achieve this, countries need to diagnose, engage in care and treat their undiagnosed populations. This will require sensitisation campaigns. However previous media campaigns have had mixed impact. We conducted a scoping review to identify and understand the impact of previous Hepatitis C media campaigns. These findings could inform the delivery of future campaigns. We searched five electronic databases for published literature on media campaigns conducted for Hepatitis C awareness, testing, and treatment in Organisation for Economic Co-operation and Development (OECD) countries since 2010. Two independent reviewers screened citations for inclusion. Additionally, we spoke to stakeholders in the Hepatitis C field in the UK and conducted a Google search to identify any unpublished literature. A quantitative synthesis was conducted to identify targeted populations, strategies and media used, aims and impact of the campaigns. A title and year of publication screening of 3815 citations resulted in 113 papers that had a full abstract screen. This left 50 full-text papers, 18 were included of which 9 (50%) were from Europe. 5 (27.8%) of campaigns targeted minority ethnicities, and 9 (50%) aimed to increase testing. A Google search identified 6 grey literature sources. Most campaigns were not evaluated for impact. Discussions with stakeholders identified several barriers to successful campaigns including lack of targeted messaging, stigmatising or accusatory messaging, and short-lived or intermittent campaign strategies. Future campaigns will likely need to be multifaceted and have multiple tailored interventions. Campaigns will need to be sizeable and robust, integrated into health systems and viewed as an ongoing service rather than one-offs.